This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the xMAP® SARS-CoV-2 Multi-Antigen IgG Assay.

The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is authorized for the detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (dipotassium EDTA).

All individuals whose specimens are tested with this assay will receive the Fact Sheet for Recipients: xMAP® SARS-CoV-2 Multi-Antigen IgG Assay.

What are the symptoms of COVID-19?
Many individuals with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing). The current information available to characterize the spectrum of clinical illness associated with COVID-19 suggests that symptoms include cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, headache, sore throat or new loss of taste or smell. Based on what is known about the virus that causes COVID-19, signs and symptoms may appear any time from 2 to 14 days after exposure to the virus. Based on preliminary data, the median incubation period is approximately 5 days, but may range from 2-14 days.

Public health officials have identified cases of COVID-19 infection throughout the world, including the United States, which may pose risks for public health. Please check the CDC webpage for the most up to date information.

What do I need to know about COVID-19 testing?
Current information on COVID-19 for healthcare providers is available at CDC’s webpage, Information for Healthcare Professionals (see links provided in “Where can I go for updates and more information” section).

• The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay can be ordered by a healthcare provider to test human serum or plasma (dipotassium EDTA) specimens to detect if there has been an adaptive immune response to COVID-19, indicating a recent or prior infection.

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088.
A positive test result with the xMAP® SARS-CoV-2 Multi-Antigen IgG Assay indicates that antibodies to SARS-CoV-2 were detected, and the individual has potentially been exposed to COVID-19.

Antibodies to SARS-CoV-2 are generally detectable in blood several days following infection. Individuals may have detectable virus present for several weeks following seroconversion. If IgG antibodies are present, it can indicate a past infection but does not exclude recently infected individuals who are still contagious. It is unknown how long antibodies to SARS-CoV-2 will remain present in the body after infection and if they confer immunity to infection. Incorrect assumptions of immunity may lead to premature discontinuation of physical distancing requirements and increase the risk of infection for individuals, their households, and the public.

False positive results may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks to individuals could include the following: a recommendation for isolation of the individual, monitoring of household or other close contacts for symptoms, isolation that might limit contact with family or friends and may increase contact with other potentially COVID-19 individuals, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or therapy, or other unintended adverse effects.

Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making patient management decisions.

All laboratories using this test must follow standard testing and reporting guidelines according to their appropriate public health authorities.

What does it mean if the specimen tests negative for IgG antibodies against virus that causes COVID-19?

A negative test result with this test means that SARS-CoV-2 specific antibodies were not present in the specimen above the limit of detection. However, individuals tested early after infection may not have detectable IgG antibody despite active infection; in addition, it is not certain that all individuals will develop a detectable IgG response to SARS-CoV-2 infection. A negative result should not be used to rule out infection. Direct testing of SARS-CoV-2 should be performed if acute infection is suspected.

The absolute sensitivity of the xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is unknown.

Risks to an individual resulting from a false negative result include: restriction of activities deemed acceptable for patients with evidence of an antibody response to SARS-CoV-2, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events.

What is an EUA?
The United States FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service’s (HHS’s) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19.

An IVD made available under an EUA has not undergone the same type of review as an FDA-approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective.

The EUA for this test is in effect for the duration of the COVID-19 declaration justifying emergency use of IVDs, unless terminated or revoked (after which the test may no longer be used).
FACT SHEET FOR HEALTHCARE PROVIDERS
xMAP® SARS-CoV-2 Multi-Antigen IgG Assay
Luminex Corporation

Where can I go for updates and more information?

**CDC webpages:**
- General: [https://www.cdc.gov/COVID19](https://www.cdc.gov/COVID19)

**FDA webpages:**
- General: [https://www.fda.gov/novelcoronavirus](https://www.fda.gov/novelcoronavirus)
- EUAs: (includes links to recipient fact sheet and manufacturer’s instructions) [https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations)

**Luminex Corporation:**
12212 Technology Blvd.
Austin, Texas 78727
USA

Website: [www.luminexcorp.com](http://www.luminexcorp.com)
Email: support@luminexcorp.com

Technical Support Telephone:
512-381-4397

North America Toll Free:
1-877-785-2323

International Toll Free:
+ 800 2939 4959

---

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 ([https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home](https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home)) or by calling 1-800-FDA-1088